These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1078 related articles for article (PubMed ID: 28561677)

  • 1. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
    Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
    Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
    Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
    Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
    Panda A; Mehnert JM; Hirshfield KM; Riedlinger G; Damare S; Saunders T; Kane M; Sokol L; Stein MN; Poplin E; Rodriguez-Rodriguez L; Silk AW; Aisner J; Chan N; Malhotra J; Frankel M; Kaufman HL; Ali S; Ross JS; White EP; Bhanot G; Ganesan S
    J Natl Cancer Inst; 2018 Mar; 110(3):316-320. PubMed ID: 29155997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
    Kelly RJ; Zaidi AH; Smith MA; Omstead AN; Kosovec JE; Matsui D; Martin SA; DiCarlo C; Werts ED; Silverman JF; Wang DH; Jobe BA
    Ann Surg; 2018 Dec; 268(6):992-999. PubMed ID: 28806299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
    Derks S; Liao X; Chiaravalli AM; Xu X; Camargo MC; Solcia E; Sessa F; Fleitas T; Freeman GJ; Rodig SJ; Rabkin CS; Bass AJ
    Oncotarget; 2016 May; 7(22):32925-32. PubMed ID: 27147580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite Instability.
    Almhanna K; Antonia S
    J Natl Cancer Inst; 2018 Mar; 110(3):221-222. PubMed ID: 29155933
    [No Abstract]   [Full Text] [Related]  

  • 10. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
    Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F
    Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
    Lin EM; Gong J; Klempner SJ; Chao J
    World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
    Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
    Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.
    Vrána D; Matzenauer M; Neoral Č; Aujeský R; Vrba R; Melichar B; Rušarová N; Bartoušková M; Jankowski J
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
    Thompson ED; Zahurak M; Murphy A; Cornish T; Cuka N; Abdelfatah E; Yang S; Duncan M; Ahuja N; Taube JM; Anders RA; Kelly RJ
    Gut; 2017 May; 66(5):794-801. PubMed ID: 26801886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
    Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P
    Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors.
    Gullo I; Carvalho J; Martins D; Lemos D; Monteiro AR; Ferreira M; Das K; Tan P; Oliveira C; Carneiro F; Oliveira P
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
    Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
    Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
    Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
    Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.